Scientists working at Centro de Regulaci?n Gen?mica (CRG) in Barcelona have managed to reprogram lymphoma and leukemia cells and stop them from being malignant. Dr. Thomas Graf and his team had previously demonstrated that it is possible to reprogram one type of…
Last week I covered India?s landmark ruling against granting Novartis patent protection for its Leukaemia and gastrointestinal cancer drug “Glivec”. The ruling received both domestic and international criticism that drove India?s trade and industry minister, Anand Sharma, to defend India?s judiciary…
Decision Tree Analysis (DTA) is one of the tools that is used to account for uncertainty and encapsulates the later decisions by the management. It is useful for analyzing sequential investment decisions at discrete points of time. In DTA, the…
With the recent rejection of Novartis? patent hitting the headlines India?s generic drug market is back in the news, this time Mumbai-based Glenmark Pharmaceuticals Ltd. is the target and Merck (MSD) is looking to sue over patent-infringement. Glenmark recently announced two anti-diabetic…
The Global Polio Eradication Initiative received a considerable boost towards achieving their funding target when the Gates? Foundation pledged$1.8bn USD towards eradicating Polio. The commitment, announced at the Global Vaccine Summit in Abu Dhabi, brings the total funds raised to $4bn,…
Hospira has announced yet another recall, this time related to copper particles found in sodium chloride injections that could potentially cause copper toxicity. Hospira, the largest US provider of sterile injectables has invested more than $375mn to upgrade its system, yet it…
April Fool?s day was anything but a joke for Novartis as India?s Supreme Court dismissed its application for patent protection of its Leukaemia and gastrointestinal cancer drug “Glivec” in India?s lucrative $13 billion-a-year drugs market. The ruling dealt a significant…
Real Options is still not widely accepted in the Bio-Pharmaceutical Industry for various reasons such as their complexity, novel concept, and inability to be recognized in real-life managerial settings. Let’s assume that a biotech company has developed a patent for a…
The Biotechnology Industry Research Assistance Council (BIRAC) will soon be launching a “Grand Challenges” programme with a $25mn investment backing from the Gates Foundation and $25mn from India?s Department of Biotechnology (IDB). The aim of the programme is to increase…
Biosimilars remain a hot topic with news yesterday that Indian generic drug giant Cipla, who only last week was praised by former president Bill Clinton, has launched the first Rheumatoid Arthritis biosimilar of Pfizer and Amgen?s blockbuster Enbrel. With its successes in producing generic chemical…